Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras by Wang, Hui et al.
 
Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by
Donor Lymphocyte Infusion in Established Mixed Allogeneic
Hematopoietic Chimeras
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Wang, Hui, Yanping Yang, Guanjun Wang, Shumei Wang, Beow
Yong Yeap, Megan Sykes, and Yong-Guang Yang. 2012. Donor
bone marrow-derived T cells inhibit GVHD induced by donor
lymphocyte infusion in established mixed allogeneic
hematopoietic chimeras. PLoS ONE 7(10): e47120.
Published Version doi:10.1371/journal.pone.0047120
Accessed February 19, 2015 11:50:42 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10511337
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAADonor Bone Marrow-Derived T Cells Inhibit GVHD
Induced by Donor Lymphocyte Infusion in Established
Mixed Allogeneic Hematopoietic Chimeras
Hui Wang
1,2, Yanping Yang
2,3, Guanjun Wang
3, Shumei Wang
2, Beow Yong Yeap
4, Megan Sykes
1, Yong-
Guang Yang
1,3*
1Columbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons, New York, New York, United States of America,
2Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 3First Bethune
Hospital of Jilin University, Changchun, Jilin, China, 4Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United
States of America
Abstract
Delayed administration of donor lymphocyte infusion (DLI) to established mixed chimeras has been shown to achieve anti-
tumor responses without graft-vs.-host disease (GVHD). Herein we show that de novo donor BM-derived T cells that are
tolerant of the recipients are important in preventing GVHD in mixed chimeras receiving delayed DLI. Mixed chimeras
lacking donor BM-derived T cells developed significantly more severe GVHD than those with donor BM-derived T cells after
DLI, even though both groups had comparable levels of total T cells at the time of DLI. Post-DLI depletion of donor BM-
derived T cells in mixed chimeras, as late as 20 days after DLI, also provoked severe GVHD. Although both CD4 and CD8 T
cells contributed to the protection, the latter were significantly more effective, suggesting that inhibition of GVHD was not
mainly mediated by CD4 regulatory T cells. The lack of donor BM-derived T cells was associated with markedly increased
accumulation of DLI-derived alloreactive T cells in parenchymal GVHD target tissues. Thus, donor BM-derived T cells are an
important factor in determining the risk of GVHD and therefore, offer a potential therapeutic target for preventing and
ameliorating GVHD in the setting of delayed DLI in established mixed chimeras.
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Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) re-
mains a potentially curative treatment for leukemias and
lymphomas, but its clinical utility has been limited by morbidity
and mortality from graft-vs.-host disease (GVHD). Thus, the
development of strategies to achieve anti-tumor responses without
GVHD has been a major goal in the field of allo-HCT. Donor
lymphocyte infusion (DLI), at doses that would induce lethal
GVHD in freshly-irradiated mice, mediates effective anti-tumor
responses without severe GVHD in established mixed hemato-
poietic chimeras (MCs) [1–3]. The lack of conditioning-induced
inflammation at the time of DLI has been shown to be an
important factor that prevents trafficking of alloreactive DLI T
cells into the epithelial GVHD target tissues in established MCs
[4]. Delayed DLI following the establishment of mixed chimerism
has also been shown to have the potential to cure hematopoietic
malignancies in clinical trials [5–7]. However, in comparison to
mouse studies in which anti-tumor effects can be reliably achieved
by delayed DLI without severe GVHD [1–3], a higher incidence
of GVHD was noted in mixed chimeric patients after DLI [5–7].
In contrast to patients in whom lymphopenia persisted for many
months after conditioning, lymphocytes recovered to normal levels
quickly in mice after allo-HCT for the establishment of mixed
chimerism. It has been shown that T cell depletion immediately
before DLI augments GVHD [8,9]. It was recently found that
established lymphocyte-deficient MCs develop GVHD after DLI,
whereas those without lymphopenia do not, indicating that
lymphopenia at the time of DLI also promotes GVHD in MCs
(Li, H. et al, manuscript submitted). In the present study, we
assessed the role of donor bone marrow (BM)-derived T cells in the
development of GVHD in established MCs after DLI. Our data
indicate that donor BM-derived T cells, particularly CD8 T cells
that develop de novo in MCs are highly protective against GVHD,
and that depletion of these T cells, either prior to or after DLI,
significantly augments GVHD regardless of whether or not
lymphopenia is present at the time of DLI.
Materials and Methods
Animals
Animals were used under protocols approved by the Subcom-
mittee on Research Animal Care of the Massachusetts General
Hospital and Columbia University Medical Center. Female wild-
type (WT), Rag2
tm1Cgn/J (RagKO), B6.129S2-Cd4
tm1Mak/J
(CD4KO), and B6.129S2-Cd8a
tm1Mak/J (CD8KO) mice on the
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e47120C57BL/6 (B6) background (H-2
b; CD45.2; Thy1.2); and B6.PL-
Thy1a/cy (H-2
b; CD45.2; Thy1.1) and BALB/c (H-2
d; CD45.2;
Thy1.2) mice were purchased from The Jackson Laboratory (Bar
Harbor, Maine). B6-LY5.2/Cr (H-2
b; CD45.1; Thy1.2) mice were
purchased from Frederick Cancer Research Facility (National
Institutes of Health, Frederick, MD). Mice were used in
experiments at 8 to 12 weeks of age and housed in a specific
pathogen-free microisolator environment.
Preparation of Mixed Allogeneic Chimeras and
Administration of DLI
Mixed chimeras (MCs) were prepared by injection of a mixture
of 0.5610
7 T cell-depleted (TCD) syngeneic BALB/c and 1.5610
7
TCD allogeneic WT, RagKO, CD4KO, or CD8KO B6 BM cells
(BMCs) into lethally irradiated (8 Gy) BALB/c mice. TCD BMCs
were prepared by depleting CD4
+ and CD8
+ cells with anti-CD4
(L3T4) and CD8a (Ly-2) microbeads using the magnetic-activated
cell sorter separation system (Miltenyi Biotec, Auburn, CA). T-cell
depletion was analyzed by flow cytometry and completeness of
depletion (,0.3% cells of the depleted phenotype remaining) was
verified in each experiment. DLI was performed using spleen cells
(1.56) from WT B6, B6-LY5.2/Cr (CD45.1) or B6.PL-Thy1
a
(Thy1.1) donors 8 weeks after initial TCD BMC injection.
Animals were randomized between cages to avoid cage-related
bias. Levels of donor chimerism in WBCs were followed up by
flow cytometry before and after DLI, in which FITC-conjugated
anti-H-2D
d mAb 34-2-12 or anti-H-2D
b mAb KH95 (BD
Biosciences San Diego, CA) was used to distinguish host and
donor cells, and in some experiments anti-CD45.1 mAb (A20) and
anti-Thy1.1 mAb were used to distinguish between DLI- and BM-
derived cells. In vivo depletion of donor BM-derived (Thy1.2
+)T
cells in established MCs was achieved by 4 injections (i.p.) of anti-
Thy1.2 mAb (clone 30-H12; the American Type Culture Collec-
tion, Manassas, VA) with a 5-day interval starting on day 10 or
day 20 after DLI from B6.PL-Thy1
a (Thy1.1) donors.
Figure 1. Donor BM-derived lymphocytes attenuate GVHD in mixed chimeras after delayed DLI. Lethally (8 Gy) irradiated BALB/c mice
were reconstituted with a mixture of TCD BALB/c plus WT (WT MCs) or RagKO (RagKO BMCs) B6 BMCs 8 weeks before DLI (i.e., injection of 1.5610
7
splenocytes) from allogeneic B6 donors. (A). Levels (%) of hematopoietic chimerism in peripheral blood measured 1 week prior to DLI. Data combined
from four independent experiments are combined (WT, n=52; KO n=47). (B). Absolute donor and recipient cell counts in WBCs (left) and spleen
(right) from WT and RagKO at week 1 post-HCT (n=3 per group). (C). Survivals (top) and body weight changes (bottom) of WT and RagKO MCs.
Combined results from 2 independent experiments are shown. (D). Histological analysis (H&E;6200) of liver and lung tissues from representative WT
and RagKO MCs at 150 days after DLI (D).
doi:10.1371/journal.pone.0047120.g001
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Carcasses were saved in 10% formalin after animals were
sacrificed for autopsy. Tissues (liver, lung and intestine) were
embedded in paraffin, sectioned, and stained with hematoxylin
and eosin. Slides were observed using an Olympus BX40 light
microscope (Olympus, Melville, NY) with 206/0.5 numeric
aperture (NA) objectives, and photographed using a Hitachi
HV-C20 color camera (Hitachi, Nashua, NH).
Statistical Analysis
Statistical analysis of survival data was performed with the log
rank test. Student’s t test was used to determine the level of
significance of differences in group means. Body weight was
transformed by taking the square root prior to fitting the trend
over time using a mixed linear model with random intercepts and
slopes assumed for each mouse. A quadratic effect was included in
the models to allow for initial weight loss followed by subsequent
gain. An unstructured covariance matrix was specified for the
random effects, while a first-order autoregressive [AR(1)] error
structure was assumed for the repeated measurements within
animals. As the treatment groups were assigned randomly, an
overall mean was assumed for the population of mouse-specific
intercepts. For the analysis focusing on the weight differences
starting at week 5, the model incorporated separate fixed effects
for the group means in place of an overall mean intercept.
Comparison between experimental groups was based on hypoth-
Table 1. Kinetics of bone marrow- and DLI-derived T cells in peripheral blood after DLI.
Wks Post-DLI Total-T Total BM-T (Recipient BM-T) Donor DLI-T
WT RagKO p WT RagKO p WT RagKO p
0 1.7260.26 1.5560.14 0.094 1.7260.26 (1.0560.21) 1.5560.14 0.094 N/A N/A N/A
2 0.5560.14 0.4760.02 0.181 0.5060.14 (0.1060.02) 0.1060.01 0.015 0.0560.01 0.3760.02 0.002
4 1.1860.02 0.2660.01 0.0004 1.0160.02 (0.0160.005) 0.0260.002 0.001 0.1760.01 0.2460.01 0.04
Numbers are absolute cell counts of total T cells (Total-T), BM-derived T cells (BM-T) and DLI-derived T cells (DLI-T) in the WBCs (mean6SDs;610
5/mL) at the indicated
time points.
doi:10.1371/journal.pone.0047120.t001
Figure 2. T cell reconstitution in mixed chimeras after delayed DLI. MCs were prepared by injection of a mixture of TCD BALB/c plus WT
(CD45.2
+) or RagKO (CD45.2
+) B6 BMCs into lethally-irradiated BALB/c mice, and injected 8 weeks with 1.5610
7 of splenocytes from B6-LY5.2/Cr
(CD45.1
+) donors. (A–B) Levels of recipient (A) and donor BM (CD45.2
+KH95
+)- and DLI (CD45.1
+KH95
+)-derived CD4 and CD8 T cells (B) in WBCs of WT
and RagKO MCs at the indicated times (7–9 mice per group were analyzed at each time point). Prior denotes 1 week prior to DLI. ***, p,0.005 for
comparison of donor DLI-derived T cells (&) between WT and RagKO MCs at the indicated time points. (C–E) Levels of donor T cells in WBCs (C),
spleen (D) and liver (E) from WT (n=3) and RagKO (n=3) MCs measured at the end (150 days post-DLI) of the experiment. Values shown are mean 6
SEM. N.S., not significant; *, p,0.05; **, p,0.01; ***, p,0.005 for comparison between WT and RagKO MCs.
doi:10.1371/journal.pone.0047120.g002
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with inference based on the F-test. Estimation by restricted
maximum likelihood (REML) was computed using SAS 9.2 (Cary,
NC). A p value of ,0.05 was considered to be significant in both
types of analysis.
Results
Lack of Donor BM-derived Lymphocytes Provokes GVHD
in Established Fully MHC-mismatched Mixed Chimeras
Receiving Delayed DLI
MCs were prepared by injecting mixed TCD BMCs from
BALB/c plus WT B6 or RagKO B6 mice into lethally-irradiated
BALB/c mice. Flow cytometric analysis at week 7 post-BM
transplantation (BMT) revealed that multilineage mixed chime-
rism was established in the MCs that received WT B6 BMCs,
while the MCs receiving RagKO BMCs showed split mixed
chimerism with myeloid (e.g., Mac-1
+) cells of both recipient and
donor origin, but lymphocytes (i.e., CD3
+ T and B220
+ B cells)
only of recipient origin (Figure 1A–B). However, the two groups of
MCs showed similar levels of total CD3
+, B220
+ and Mac-1
+ cells
(Figure 1A–B).
To determine the role of donor BM-derived lymphocytes in
DLI-mediated GVHD, WT and RagKO MCs were given DLI
from WT B6 donors at week 8 post-BMT, and followed for body
weight changes, survival rates and histological GVHD. Although
only a small difference was seen in survival rates between WT
(92.3%) and RagKO (66.7%) MCs (Figure 1C), the latter MCs
showed significantly more severe body weight loss than the former
group (Figure 1C; p,0.001). WT MCs exhibited moderate body
weight loss early after DLI followed by recovery, whereas RagKO
MCs showed continued weight loss throughout the experiment
(Figure 1C). Histological examination confirmed severe inflam-
matory infiltrates and the associated tissue lesions in GVHD target
organs (i.e., lung and liver) from the long-term surviving RagKO,
but not WT, MCs (Figure 1D). These results indicate that the lack
of pre-existing donor BM-derived lymphocytes is an important risk
factor for persistent GVH responses and GVHD in established
MCs after delayed DLI.
Increased Expansion and Survival of Donor DLI-derived
Allogeneic T Cells in RagKO Mixed Chimeras
We also assessed the kinetics of recipient and donor T cells in
peripheral blood of WT vs. RagKO MCs after DLI. In order to
distinguish between donor BM- and DLI-derived T cells, MCs
were prepared by injecting mixed TCD BMCs from BALB/c plus
WT (CD45.2
+) or RagKO (CD45.2
+) B6 mice into lethally-
irradiated BALB/c mice, and injected 8 weeks later with
splenocytes from congeneic B6-LY5.2/Cr (CD45.1
+) donors. In
both WT and RagKO MCs, recipient type (BALB/c) T cells were
rapidly eliminated within 2 weeks after DLI (Figure 2A and
Table 1). Compared to WT MCs, in which donor BM-derived T
cells remained the major donor T cell population, a significantly
greater expansion of DLI-derived donor (CD45.1
+KH95
+) T cells
was seen in RagKO MCs at weeks 2 and 4 post-DLI (Figure 2B
and Table 1). The fact that lack of donor BM-derived lymphocytes
was associated with more severe GVHD and greater expansion of
DLI-derived T cells in RagKO MCs (and vice versa in WT MCs)
suggests that donor BM-derived non-alloreactive T cells in
established MCs may suppress the alloresponses of DLI T cells.
We also measured T cell chimerism in long-term surviving MC
recipients that were sacrificed at day 150 post-DLI. All these long-
term surviving WT and RagKO MCs became full donor chimeras
(data not shown), indicating complete elimination of recipient
hematopoietic cells by DLI-induced alloresponses. DLI-derived
donor T cells were barely detected in peripheral blood or spleen
from both WT and RagKO MCs, while WT MCs demonstrated
good reconstitution with donor BM-derived T cells in these tissues
(Table 2 and Figure 2C,D). Surprisingly, despite the extremely
poor T cell repopulation in lymphoid tissues in RagKO MCs, the
levels of donor T cells in the liver of these mice were comparable
to those of WT MCs (Figure 2E). However, unlike the WT MCs,
in which almost all T cells were donor BM-derived, T cells in the
liver of RagKO MCs were all DLI-derived (Table 2) and
presumably long-term surviving alloreactive T cells. The data
correlated well with the pathological findings (Figure 1D) in
RagKO MCs.
Both Donor BM-derived CD4 and CD8 T Cells Mediate
Protection Against GVHD Induced by DLI in Established
Mixed Chimeras
The potential role of donor BM-derived CD4 and CD8 T cells
in regulation of DLI T cell alloresponses was assessed by
comparing GVHD development among WT MCs, RagKO
MCs, and MCs that were prepared by injection of syngeneic plus
CD4KO (CD4KO MCs) or CD8KO (CD8KO MCs) allogeneic
BMCs. Although significant differences were detected in the levels
of CD4 and CD8 T cell subsets (Table 3), the overall T cell levels
were comparable among these MCs prior to DLI (Figure 3A).
Consistent with the results in Figure 1, DLI given at week 8
induced significantly more severe GVHD in RagKO MCs than in
WT MCs (Figure 3B). Although CD4KO MCs showed more
profound body weight loss starting at 5 weeks than WT MCs
(p,0.01), these MCs had less severe GVHD, as shown by lower
Table 2. Accumulation of donor DLI-derived T cells in parenchymal, but not lymphoid, tissues in RagKO chimeras (Mean6SDs).
T-cell Origin WBC (x10
3/ml) Spleen (x10
5) Liver (x10
4)
WT RagKO p WT RagKO p WT RagKO p
CD4
Donor DLI 0.0160.01 0.3360.06 0.187 0.2260.06 0.5760.37 0.096 0.4960.4 10.266.50 0.029
Donor BM 32.1617.1 N/A N/A 18.37620.09 N/A N/A 8.0767.11 N/A N/A
CD8
Donor DLI 0.3460.57 0.3560.6 0.492 0.1960.11 0.560.44 0.166 0.7560.42 17.369.26 0.018
Donor BM 37620.4 N/A N/A 9.7368.12 N/A N/A 20.4767.37 N/A N/A
N/A, not available.
doi:10.1371/journal.pone.0047120.t002
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CD8KO (p,0.001 starting at 5 weeks after DLI) and RagKO
(p,0.05 for the entire period of observation) MCs (Figure 3B).
The survival rates and body weight changes were, in general,
comparable between CD8KO and RagKO MCs, with the
exception that the latter group showed significantly more severe
body weight loss starting at 5 weeks after DLI (p,0.05). These
results indicate that both BM-derived CD4 and CD8 T cells
mediate protection against DLI-induced GVHD, but the latter cell
population is more effective.
Depletion of Donor BM-derived T Cells in Established
Mixed Chimeras after DLI Provokes GVHD
Although lymphopenia at the time of DLI may potentially
promote GVHD [8], RagKO MCs did not show lymphopenia
compared to WT MCs at the time of DLI (Figure 1A–B; Table 1).
However, lymphopenia was detected at the later times in RagKO
MCs when recipient BM-derived cells were eliminated (Table 1;
Figure 2), suggesting that the continuous presence of donor BM-
derived T cells might be required to inhibit GVHD. To address
this question, we assessed the effect of post-DLI depletion of donor
BM-derived T cells on GVHD. WT MCs were prepared by
injection of BALB/c and Thy1.2
+ B6 mouse BMCs into lethally-
irradiated BALB/c mice (Thy1.2
+). These MCs received DLI 8
weeks later from B6.PL-Thy1a (Thy1.1
+) donors. We treated these
MCs with anti-Thy1.2 mAb to deplete BM-derived T cells (or
with Rat IgG as the control) starting at day 10 or day 20 after DLI,
when recipient-type T cells were almost completely eliminated
(Table 1; Figure 2A). MCs treated with anti-Thy1.2 mAb starting
at either 10 or 20 days after DLI developed significantly more
severe GVHD than rat IgG-treated controls (Figure 4). Anti-
Thy1.2 mAb-treated MCs showed significantly increased mortal-
ity (Figure 4A), as well as more severe body weight loss (p,0.05;
Figure 4B), hunched posture, and diarrhea before death compared
to rat IgG-treated control MCs. Furthermore, histological analysis
revealed more severe inflammatory infiltrates and tissue lesions in
GVHD target organs (e.g., liver, lung and colon) from MCs that
were treated with anti-Thy1.2 mAb compared to those from rat
IgG-treated controls (Figure 4C).
Some MCs that were treated with anti-Thy1.2 or rat IgG
starting at day 10 post-DLI were sacrificed 5 and 20 days after first
antibody injection (i.e., 15 and 30 days after DLI), and DLI-
derived donor T cell expansion in peripheral blood, spleen and
liver was measured by flow cytometric analysis. The levels of
Thy1.2
+ CD4 and CD8 T cells in MCs treated with anti-Thy1.2
were significantly reduced compared to rat IgG-treated controls,
reflecting an efficient T cell depletion by anti-Thy1.2 mAb
(Figure 5A). With the exception of peripheral blood, depletion of
donor BM-derived T cells did not result in a significant reduction
in total CD8 T cell levels in these tissues (Figure 5B). Anti-Thy1.2-
and rat IgG-treated MCs also showed comparable levels of total
CD4 T cells in spleen at day 15 post-DLI and in liver at days 15
and 30 post-DLI (Figure 5B). However, depletion of donor BM-
derived Thy1.2
+ T cells led to significantly greater expansion and/
or survival of DLI-derived Thy1.1
+ T cells in all tissues examined
(Figure 5C). Taken together, these results indicate that the
continuous presence of donor BM-derived T cells is essential for
preventing GVHD in established MCs after DLI.
Discussion
The present study provides evidence that donor BM-derived T
cells, particularly CD8 T cells that develop post-BMT in the
presence of recipient antigens, are highly protective against
GVHD in established MCs receiving delayed DLI. DLI induced
significantly more severe GVHD in RagKO MCs that had no
donor BM-derived T cells at the time of DLI or in WT MCs that
were depleted of donor BM-derived T cells after DLI compared to
untreated WT MCs. The lack of donor BM-derived T cells was
associated with markedly increased expansion and infiltration into
GVHD target tissues of DLI-derived alloreactive T cells.
Lymphopenia has the potential to promote anti-tumor responses
of adoptively transferred T cells by increasing expansion of T cells
with associated development of effector function [10], decreasing
Figure 3. Both donor BM-derived CD4 and CD8 T cells are protective against GVHD in mixed chimeras receiving delayed DLI.
Lethally (8 Gy) irradiated BALB/c mice were reconstituted with a mixture of TCD BALB/c plus WT (WT MC; n=7), RagKO (RagKO MC; n=6), CD4KO
(CD4KO MC; n=7), or CD8KO (CD8KO MC; n=8) B6 BMCs 8 weeks before DLI from WT B6 donors. (A) Hematopoietic chimerism in WBCs measI can
hear Kazured one week prior to DLI. (B) Survival (left) and body weight changes (right).
doi:10.1371/journal.pone.0047120.g003
Table 3. T cell reconstitution in peripheral blood prior to DLI.
Group Total CD4 p* Total CD8 p*
WT MC 16.963.1 2.561.5
RagKO MC 17.767.6 0.417 2.061.2 0.250
CD4KO MC 9.765.0 0.004 10.462.8 ,0.001
CD8KO MC 19.065.2 0.178 0.860.2 0.010
Data are presented as percentages of the indicated cell populations
(mean6SDs) in WBCs.
*depicts the p value for comparison between the indicated group and WT MCs;
N/A, not available.
doi:10.1371/journal.pone.0047120.t003
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failing to prevent microbial translocation-induced inflammatory
stimuli [13]. Total T cell depletion immediately before allo-HCT
has been shown to promote GVHD both in human and murine
models [9,14]. However, the increased risk for GVHD observed in
the established RagKO MCs following DLI in the present study
was not caused by lack of T cells at the time of DLI, because
RagKO MCs did not show reduced T cell counts compared to
WT MCs at the time of DLI (Figure 1 and Table 1) and depletion
of donor BM-derived T cells 20 days after DLI also significantly
exacerbated GVHD in established WT MCs (Figure 4).
DLI-derived T cells were barely detectable in the blood and
spleen from long-term surviving MCs (Table 2), regardless of the
presence or absence of donor BM-derived T cells. As a
consequence of the loss of DLI-derived cells, lymphoid tissues in
RagKO, but not WT, MCs were found to be lymphopenic at later
times (Figure 2C,D), which was associated with a more severe
GVHD and increased accumulation of DLI-derived alloreactive T
cells in parenchymal GVHD target tissues. This is consistent with
the previous finding that alloreactive T cells have impaired ability
to reconstitute host lymphoid organs in allo-HCT recipients [15–
17]. These results indicate that MCs lacking donor BM-derived T
cells will likely develop lymphopenia eventually after DLI when
recipient hematopoietic cells are eliminated by GVHR. Such post-
DLI lymphopenia developing after the onset of GVHD is likely to
exacerbate GVHD by providing an additional stimulus driving
continuous expansion of alloreactive effector/memory T cells.
Furthermore, persistent lymphopenia may also provoke GVHD by
diminishing protection against microbial translocation-induced
inflammatory stimuli [13], a potent risk factor for GVHD [4].
Infusion of donor CD4
+CD25
+ Tregs, which are critical for
maintenance of self-tolerance and prevention of autoimmunity,
has been found to effectively inhibit GVHD [18,19]. Although
various types of Tregs have been reported, CD4
+CD25
+Foxp3
+
Tregs are considered the most robust Treg population [20]. In
lethally-irradiated full donor chimeras, it was found that depletion
of recipient T cells prior to DLI promotes GVHD, and that the
exacerbation of GVHD in this model was due to removing
CD4
+CD8
2 and CD4
2CD8
2, but not CD8
+, Tregs [8,14].
However, our data indicate that that the protective effect of donor
BM-derived T cells against GVHD induced by delayed DLI in
established chimeras was not mediated predominantly by CD4
+
Tregs. Although both CD4 and CD8 T cells were found to be
protective against GVHD induced by DLI in established MCs, the
Figure 4. Post-DLI depletion of donor BM-derived T cells exacerbates GVHD in mixed chimeras. Lethally (8 Gy) irradiated BALB/c mice
were reconstituted with a mixture of TCD BALB/c plus WT B6 (Thy1.2+) BMCs 8 weeks before DLI (i.e., injection of 1.5610
7 splenocytes) from B6.PL-
Thy1a (Thy1.1+) donors. Donor BM-derived T cell depletion in these MCs was performed by injection (i.p.) of anti-Thy1.2 antibodies starting at day 10
(n=8) or day 20 (n=9) after DLI as described in Materials and Methods. Control MCs (n=8) were treated with Rat IgG. Shown are survival (A), body
weight changes (B) and histological analysis (H&E;6100) of liver, lung and colon from representative MCs at day 20-post antibody treatment (i.e., 30
days post-DLI) (C).
doi:10.1371/journal.pone.0047120.g004
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than in CD4KO MCs suggests that donor BM-derived CD8 T
cells provide more potent protection than donor BM-derived CD4
T cells. It has been reported that CD4 Tregs developing in the
absence of CD8 T cells exhibit poor suppressive function in a
mouse allergic lung disease model [21]. However, CD4 Tregs in
the CD8KO MCs are expected to be functional, as CD8 T cells
were present in these MCs both prior to (recipient BM-derived
CD8 T cells) and after (recipient BM- and DLI-derived CD8 T
cells) DLI. Furthermore, the role for CD8 T cells in CD4 Treg
function may not apply to all immunological settings. It has been
reported that a treatment that inhibits alloresponses via a Treg-
dependent mechanism can also significantly prolong allograft
survival in CD8 KO mice [22]. Furthermore, CD8KO BMT in
lethally-irradiated mice can lead to reconstitution of functional
CD4 Tregs that are capable of suppressing GVHD [8]. Taken
together, CD4 Tregs in CD8KO MCs are likely to be functional
and therefore, the more severe GVHD in CD8KO MCs than in
CD4KO MCs after DLI suggests that the protective effect against
GVHD of donor BM-derived T cells is attributed more to donor
BM-derived CD8 than CD4 T cells. Although the development
and function of CD8
+Foxp3
+ Tregs are less understood than CD4
Tregs, such Treg cell populations have been identified in various
models [23–26]. Unlike CD4
+Foxp3
+ Tregs, CD8
+Foxp3
+ Treg
function was found to be positively regulated by IL-6 [27], a
cytokine that has been shown to increase in mice with GVHD
[28]. Further studies are needed to determine whether the
protective effect against GVHD of donor BM-derived CD8 T
cells is attributable to the induction of CD8
+Foxp3
+ Tregs.
In summary, the present study demonstrates that donor BM-
derived T cells are an important factor determining the risk of
GVHD in established MCs receiving delayed DLI. Exacerbation
of GVHD was seen not only in MCs having no donor BM-derived
T cells at the time of DLI, but also in those losing donor BM-
derived T cells a few weeks after DLI. Thus, the level of donor
BM-derived T cells in MCs may provide a better outcome
Figure 5. Donor DLI-derived T cell expansion following the depletion of donor BM-derived T cells. MC preparation and DLI
administration were performed as detailed in the legend to Figure 4, and treated with anti-Thy1.2 or Rat IgG starting at day 10 post-DLI. MCs were
sacrificed 5 (n=3 per group) and 20 (Rat IgG, n=3; aThy1.2, n=4) days after antibody treatment (i.e., 15 and 30 days after DLI, respectively), and the
levels of Th1.1+ and Thy1.2+ T cells in various tissues were determined by flow cytometry using anti-Thy1.1 mAb. (A) Representative staining profiles
(Left) and levels (mean6SEM) of Thy1.2
+ (i.e., cells stained negative for Thy1.1) T cells in various tissues at day 5 post-antibody treatment (15 day after
DLI). (B,C) Numbers (mean6SEM) of total (B) and DLI-derived Thy1.1+ (C) T cells (CD8 and CD4 T cells are shown at the top and bottom panels,
respectively) in WBC, spleen and liver at the indicated time points. *, p,0.05; **, p,0.01; ***, p,0.005.
doi:10.1371/journal.pone.0047120.g005
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optimization of the timing of DLI administration. Furthermore,
because donor T cells developing de novo in the recipients are
tolerant of both donor and recipient antigens [29], our results
indicate that improving T cell development from donor BM cells
and infusing allodepleted or non-alloreactive donor T cells may
offer an effective means to prevent or inhibit GVHD induced by
delayed DLI in established MCs.
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